NCT04388319View on ClinicalTrials.gov

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

June 4, 2021

Study Completion Date

September 15, 2021

Conditions
Smoking Cessation
Interventions
DRUG

Zonisamide

Zonisamide (100 mg/daily) for 12 weeks.

DRUG

Bupropion

Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.

OTHER

Halo G6 e-cigarette

G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.

Trial Locations (2)

27617

Rose Research Center, Raleigh

28262

Rose Research Center, Charlotte

All Listed Sponsors
collaborator

Foundation for a Smoke Free World INC

OTHER

lead

Rose Research Center, LLC

INDUSTRY

NCT04388319 - Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes | Biotech Hunter | Biotech Hunter